Aprocitentan reduced office systolic blood pressure at 4 weeks by a mean difference of -3.8 mm Hg compared to placebo (97.5% CI -6.8 to -0.8) in patients with resistant hypertension.
Does aprocitentan reduce office systolic blood pressure in patients with resistant hypertension?
Aprocitentan, the first approved dual endothelin receptor antagonist, significantly reduces systolic blood pressure in patients with resistant hypertension.
Mean Difference: -3.8 (95% CI -6.8–-0.8)
Absolute Event Rate: -15.3% vs -11.5%
Hypertension affects approximately 47.7% of US adults, with higher rates observed in men (50.8%) compared with women (44.6%). Risk factors and characteristics such as age, family history, race, and ethnicity also can increase the risk of developing high blood pressure and can make treatment more difficult. Aprocitentan is the first dual endothelin receptor antagonist approved for the treatment of resistant hypertension. The PRECISION clinical trial resulted in a mean change in office systolic blood pressure at 4 weeks of -15.3 mm Hg for aprocitentan 12.5 mg, -15.2 mm Hg for aprocitentan 25 mg, and -11.5 mm Hg for placebo, for a difference versus placebo of -3.8 mm Hg (97.5% confidence interval -6.8 to -0.8,
Powell et al. (Mon,) conducted a review in resistant hypertension. Aprocitentan vs. placebo was evaluated on mean change in office systolic blood pressure (MD -3.8 mm Hg, 95% CI -6.8 to -0.8). Aprocitentan reduced office systolic blood pressure at 4 weeks by a mean difference of -3.8 mm Hg compared to placebo (97.5% CI -6.8 to -0.8) in patients with resistant hypertension.